

US CPI Eases, But Here's Why The Fed Is Flying Blind On Inflation

U.S. CPI (m/m%; y/y%), February:

Actual: 0.2 / 1.5

Scotia: 0.3 / 1.5

Consensus: 0.2 / 1.6

Prior: Unrevised from 0.0 / 1.6

U.S. Core CPI (m/m%; y/y%), February :

Actual: 0.1 / 2.1

Scotia: 0.3 / 2.1

Consensus: 0.2 / 2.2

Prior: Unrevised from 0.2 / 2.2

- US CPI decelerated a touch on both headline and core by coming in lower than consensus expected and in line with my estimates for both.** Headline CPI eased to 1.5% y/y and core CPI pulled back to 2.1% y/y. Breadth was mixed. The broad takeaway is that there is nothing really terribly new here to the Fed's narrative.
- Indeed, who cares about CPI. More seriously, the Fed is arguably flying blind on what is happening to price pressures because the shutdown effects have driven an unusual two-month wedge between freshness of its preferred PCE gauges versus CPI.** I'll therefore wait to reserve judgement on what's happening to inflation as the Fed sees its until we get core PCE gauges for January and February. I find a lot of the commentary on the implications to today's CPI update (and the one before it) ignore Fed-101 in that the CPI is not a terribly good inflation measure relative to the superior PCE gauge that we simply don't have readings for in 2019. To be standing here in March with no inflation data of relevance to the Fed merits caution indeed, but there is still two-tailed risk to that caution.
- Core CPI has decelerated from a recent peak of 2.4% y/y in July to 2.1% now. **I think a significant driver of the deceleration has been pass-through of a strong dollar if it passes through to PCE which is a big caution (more later).** By corollary, this flags uncertainty going forward given how much stronger the dollar has been that we had anticipated over the past year. The broad dollar index sharply appreciated throughout 2018 and then began to wane from December through to the end of January before going on another upward trend since then. Fed estimates suggest that a 10% appreciation in the broad dollar index shaves ½% off core PCE within six months and just over ¼% within one year as the effects dissipate. There are no immediate near-term signs that the broad dollar is going to weaken and so this is a significant risk to our inflation and hence Fed views over H2.
- For now, the readings support the Fed's contention that there is no immediate source of inflation pressure that merits a response in the face of the Fed's uncertainties that are governing the outlook.** There are also no immediate sources of pressure to adjust policy in the other direction and we'll have to wait for how this translates into the Fed's preferred PCE inflation gauge on March 29th. Core PCE did not peak as high as core CPI last

CONTACTS


Derek Holt, VP & Head of Capital Markets Economics
416.863.7707

Scotiabank Economics
derek.holt@scotiabank.com

Chart 1




Chart 2



Fall and may not be as sensitive to the influences upon CPI. For now, CPI matters to TIPS and little else until we get the PCE gauges. The connection between the two price measures is shown in chart 1. There are a lot of measurement differences between the two concepts (e.g. CPI underweights medical care and PCE adjusts weights dynamically as spending patterns shift as opposed to periodic weight adjustments in CPI) and so what happens to CPI doesn't necessarily translate well into PCE. In any event, we still only have PCE up until December thanks to shutdown effects. We need PCE for January on March 29th and then February soon thereafter to more thoroughly judge risks to inflation the way the Fed sees it. Soon after PCE for January and February finally arrives, we'll then be flying blind again as CPI for March arrives and PCE lags again.

- Underlying breadth arguments are mixed. Upside influences to the month-ago price changes came from food/beverages (+0.4%), apparel (+0.3%), energy (+0.4%), OER (+0.3%). Downsides came from services (+0.1%), recreation (-0.4%), computers (-0.9%), medical care (-0.2%) and transportation (+0.1%). Chart 3 shows the weighted contributions to year-over-year CPI by basket component. For example, rent of shelter is the biggest contributor that is on its own adding a weighted 1.1% to year-ago CPI.
- Overall I don't think today's data changes anything for the inflation outlook. A first half softening isn't surprising but a second half stabilization with possible upward drift is feasible as: output gap effects have lagging positive influences; as real wage gains accelerate; and if the broad dollar stabilizes as a disinflationary influence. The dollar has been a lot stronger for longer than anticipated so its role in driving pass-through arguments to inflation is highly uncertain going forward.
- Prescription drug prices soared in month-ago terms but plunged in year-ago terms (see chart 2). Either way, they carry a modest 1.313% weight in CPI and fell by 1.2% y/y and 1% m/m. That shaves a negligible amount off headline CPI.
- I think there is a similar argument for the mixed influences of auto prices on the month-ago and year-ago readings. New vehicles carry a 3.74% weight and used vehicles are weighted at 2.4%. New increased 0.3% y/y and fell 0.2% m/m while used increased 1.1% y/y and fell 0.7% m/m.

Chart 3 Weighted Contributions To Year-Ago U.S. CPI Change



Sources: Scotiabank Economics, BLS.

This report has been prepared by Scotiabank Economics as a resource for the clients of Scotiabank. Opinions, estimates and projections contained herein are our own as of the date hereof and are subject to change without notice. The information and opinions contained herein have been compiled or arrived at from sources believed reliable but no representation or warranty, express or implied, is made as to their accuracy or completeness. Neither Scotiabank nor any of its officers, directors, partners, employees or affiliates accepts any liability whatsoever for any direct or consequential loss arising from any use of this report or its contents.

These reports are provided to you for informational purposes only. This report is not, and is not constructed as, an offer to sell or solicitation of any offer to buy any financial instrument, nor shall this report be construed as an opinion as to whether you should enter into any swap or trading strategy involving a swap or any other transaction. The information contained in this report is not intended to be, and does not constitute, a recommendation of a swap or trading strategy involving a swap within the meaning of U.S. Commodity Futures Trading Commission Regulation 23.434 and Appendix A thereto. This material is not intended to be individually tailored to your needs or characteristics and should not be viewed as a “call to action” or suggestion that you enter into a swap or trading strategy involving a swap or any other transaction. Scotiabank may engage in transactions in a manner inconsistent with the views discussed this report and may have positions, or be in the process of acquiring or disposing of positions, referred to in this report.

Scotiabank, its affiliates and any of their respective officers, directors and employees may from time to time take positions in currencies, act as managers, co-managers or underwriters of a public offering or act as principals or agents, deal in, own or act as market makers or advisors, brokers or commercial and/or investment bankers in relation to securities or related derivatives. As a result of these actions, Scotiabank may receive remuneration. All Scotiabank products and services are subject to the terms of applicable agreements and local regulations. Officers, directors and employees of Scotiabank and its affiliates may serve as directors of corporations.

Any securities discussed in this report may not be suitable for all investors. Scotiabank recommends that investors independently evaluate any issuer and security discussed in this report, and consult with any advisors they deem necessary prior to making any investment.

This report and all information, opinions and conclusions contained in it are protected by copyright. This information may not be reproduced without the prior express written consent of Scotiabank.

™ Trademark of The Bank of Nova Scotia. Used under license, where applicable.

Scotiabank, together with “Global Banking and Markets”, is a marketing name for the global corporate and investment banking and capital markets businesses of The Bank of Nova Scotia and certain of its affiliates in the countries where they operate, including, Scotiabanc Inc.; Citadel Hill Advisors L.L.C.; The Bank of Nova Scotia Trust Company of New York; Scotiabank Europe plc; Scotiabank (Ireland) Limited; Scotiabank Inverlat S.A., Institución de Banca Múltiple, Scotia Inverlat Casa de Bolsa S.A. de C.V., Scotia Inverlat Derivados S.A. de C.V. – all members of the Scotiabank group and authorized users of the Scotiabank mark. The Bank of Nova Scotia is incorporated in Canada with limited liability and is authorised and regulated by the Office of the Superintendent of Financial Institutions Canada. The Bank of Nova Scotia is authorised by the UK Prudential Regulation Authority and is subject to regulation by the UK Financial Conduct Authority and limited regulation by the UK Prudential Regulation Authority. Details about the extent of The Bank of Nova Scotia’s regulation by the UK Prudential Regulation Authority are available from us on request. Scotiabank Europe plc is authorised by the UK Prudential Regulation Authority and regulated by the UK Financial Conduct Authority and the UK Prudential Regulation Authority.

Scotiabank Inverlat, S.A., Scotia Inverlat Casa de Bolsa, S.A. de C.V., and Scotia Derivados, S.A. de C.V., are each authorized and regulated by the Mexican financial authorities.

Not all products and services are offered in all jurisdictions. Services described are available in jurisdictions where permitted by law.